284 related articles for article (PubMed ID: 20180858)
21. Evaluation of novel Brucella melitensis unmarked deletion mutants for safety and efficacy in the goat model of brucellosis.
Kahl-McDonagh MM; Elzer PH; Hagius SD; Walker JV; Perry QL; Seabury CM; den Hartigh AB; Tsolis RM; Adams LG; Davis DS; Ficht TA
Vaccine; 2006 Jun; 24(24):5169-77. PubMed ID: 16697090
[TBL] [Abstract][Full Text] [Related]
22. The use of green fluorescent protein as a marker for Brucella vaccines.
Chacón-Díaz C; Muñoz-Rodríguez M; Barquero-Calvo E; Guzmán-Verri C; Chaves-Olarte E; Grilló MJ; Moreno E
Vaccine; 2011 Jan; 29(3):577-82. PubMed ID: 21056079
[TBL] [Abstract][Full Text] [Related]
23. Brucella melitensis Rev. 1 and Brucella abortus 45-20 vaccines in goats: serologic tests.
Jones LM; García-Carrillo C; Alton GG
Am J Vet Res; 1973 Feb; 34(2):199-202. PubMed ID: 4631096
[No Abstract] [Full Text] [Related]
24. Protection of BALB/c mice against homologous and heterologous species of Brucella by rough strain vaccines derived from Brucella melitensis and Brucella suis biovar 4.
Winter AJ; Schurig GG; Boyle SM; Sriranganathan N; Bevins JS; Enright FM; Elzer PH; Kopec JD
Am J Vet Res; 1996 May; 57(5):677-83. PubMed ID: 8723881
[TBL] [Abstract][Full Text] [Related]
25. Partial protection induced by Salmonella based Brucella vaccine candidate in pregnant guinea pigs.
Lalsiamthara J; Senevirathne A; Lee JH
Vaccine; 2019 Feb; 37(7):899-902. PubMed ID: 30661832
[TBL] [Abstract][Full Text] [Related]
26. Studies on the immune protection to murine experimental brucellosis conferred by Brucella fractions. I. Positive role of immune serum.
Bascoul S; Cannat A; Huguet MF; Serre A
Immunology; 1978 Aug; 35(2):213-21. PubMed ID: 750371
[TBL] [Abstract][Full Text] [Related]
27. [Vaccination against human brucellosis. 2 years of experience].
Bentejac MC; Biron G; Bertrand A; Bascoul S
Dev Biol Stand; 1984; 56():531-5. PubMed ID: 6436111
[No Abstract] [Full Text] [Related]
28. The protein moiety of Brucella abortus outer membrane protein 16 is a new bacterial pathogen-associated molecular pattern that activates dendritic cells in vivo, induces a Th1 immune response, and is a promising self-adjuvanting vaccine against systemic and oral acquired brucellosis.
Pasquevich KA; García Samartino C; Coria LM; Estein SM; Zwerdling A; Ibañez AE; Barrionuevo P; Oliveira FS; Carvalho NB; Borkowski J; Oliveira SC; Warzecha H; Giambartolomei GH; Cassataro J
J Immunol; 2010 May; 184(9):5200-12. PubMed ID: 20351187
[TBL] [Abstract][Full Text] [Related]
29. Adverse events in humans associated with accidental exposure to the livestock brucellosis vaccine RB51.
Ashford DA; di Pietra J; Lingappa J; Woods C; Noll H; Neville B; Weyant R; Bragg SL; Spiegel RA; Tappero J; Perkins BA
Vaccine; 2004 Sep; 22(25-26):3435-9. PubMed ID: 15308369
[TBL] [Abstract][Full Text] [Related]
30. Vaccines, vaccination in brucellosis.
Plommet M; Serre A; Fensterbank R
Ann Inst Pasteur Microbiol; 1987; 138(1):117-21. PubMed ID: 3300716
[No Abstract] [Full Text] [Related]
31. Alternative strategies for vaccination to brucellosis.
Pascual DW; Yang X; Wang H; Goodwin Z; Hoffman C; Clapp B
Microbes Infect; 2018; 20(9-10):599-605. PubMed ID: 29287984
[TBL] [Abstract][Full Text] [Related]
32. Intradermal immunization with outer membrane protein 25 protects Balb/c mice from virulent B. abortus 544.
Goel D; Bhatnagar R
Mol Immunol; 2012 Jun; 51(2):159-68. PubMed ID: 22464098
[TBL] [Abstract][Full Text] [Related]
33. Pathogenesis and immune response in Brucella infection acquired by the respiratory route.
Ferrero MC; Alonso Paiva IM; Muñoz González F; Baldi PC
Microbes Infect; 2020 Oct; 22(9):407-415. PubMed ID: 32535086
[TBL] [Abstract][Full Text] [Related]
34. Evaluation of Brucella melitensis B115 as rough-phenotype vaccine against B. melitensis and B. ovis infections.
Adone R; Francia M; Ciuchini F
Vaccine; 2008 Sep; 26(38):4913-7. PubMed ID: 18675869
[TBL] [Abstract][Full Text] [Related]
35. Protective role of antibodies induced by Brucella melitensis B115 against B. melitensis and Brucella abortus infections in mice.
Adone R; Francia M; Pistoia C; Petrucci P; Pesciaroli M; Pasquali P
Vaccine; 2012 Jun; 30(27):3992-5. PubMed ID: 22521283
[TBL] [Abstract][Full Text] [Related]
36. Immunologic properties of soluble materials from Brucella species.
Bowser DV; Foster JW; Cooper MD
Am J Vet Res; 1979 Feb; 40(2):256-9. PubMed ID: 464362
[TBL] [Abstract][Full Text] [Related]
37. Ovine brucellosis: repeated vaccination with Rev 1 vaccine and the prevalence of the disease in the Winburg district.
Erasmus JA; Bergh EC
J S Afr Vet Assoc; 1985 Dec; 56(4):205-8. PubMed ID: 3836306
[TBL] [Abstract][Full Text] [Related]
38. Escheriosome-mediated delivery of recombinant ribosomal L7/L12 protein confers protection against murine brucellosis.
Mallick AI; Singha H; Khan S; Anwar T; Ansari MA; Khalid R; Chaudhuri P; Owais M
Vaccine; 2007 Nov; 25(46):7873-84. PubMed ID: 17931756
[TBL] [Abstract][Full Text] [Related]
39. Assessment of serological response of young and adult sheep to conjunctival vaccination with Rev-1 vaccine by fluorescence polarization assay (FPA) and other serological tests for B. melitensis.
Stournara A; Minas A; Bourtzi-Chatzopoulou E; Stack J; Koptopoulos G; Petridou E; Sarris K
Vet Microbiol; 2007 Jan; 119(1):53-64. PubMed ID: 16973307
[TBL] [Abstract][Full Text] [Related]
40. [Phenol-insoluble vaccine against human brucellosis: evaluation of the immunogenic power in guinea pigs].
Bolpe J; de Lapenta DF; García-Carrillo C
Rev Inst Med Trop Sao Paulo; 1991; 33(1):23-7. PubMed ID: 1843392
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
